Skip to content

Search

Delivering smart drugs into cells

The Drug Discovery Unit has been finding ways for smart drugs to penetrate deep into cells and attacking their disease targets while causing fewer side effects

A cell change that drives leukaemia

It is now known that the HOX11 gene is permanently activated in the leukaemia cells and it drives the disease.

New imaging equipment to boost children's cancer research

A cutting edge cancer imaging facility will help specialist children's cancer researchers at Perth's Telethon Institute for Child Health Research.

New test proves effective in more cancers

Avantogen Limited (ACU:ASX) today announced that cancer researchers at Perth's The Kids for Child Health Research (TICHR) and Avantogen Limited

National study to unravel triggers for childhood leukaemia

A national study is investigating diet, chemical exposure and genetic factors in a new bid to unravel the causes of childhood leukaemia.

WA families to help find triggers for childhood leukaemia

West Australian families are being asked to play a vital role in a major new national study to unravel the causes of childhood leukaemia.

New treatments on horizon for rarest child brain cancers

The WA Kids Cancer Centre has a suite of world-leading research projects to unlock new treatments for childhood cancers.

Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

Citation: Sek K, Chen AXY, Cole T, Armitage JD, Tong J, ……… Waithman J, Parish IA, et al. Tumor site-directed A1R expression enhances CAR T cell

Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma

Chemotherapy often kills a large fraction of cancer cells but leaves behind a small population of drug-tolerant persister cells. These persister cells survive drug treatments through reversible, non-genetic mechanisms and cause tumour recurrence upon cessation of therapy. Here, we report a drug tolerance mechanism regulated by the germ-cell-specific H3K4 methyltransferase PRDM9. 

IDH mutant high-grade gliomas

Gliomas are the most common type of malignant primary central nervous system (CNS) tumors, resulting in significant morbidity and mortality in children and adolescent and young adult (AYA) patients. The discovery of mutations in isocitrate dehydrogenase (IDH) genes has dramatically changed the classification and understanding of gliomas.  IDH mutant gliomas have distinct clinical, pathological, and molecular features including a favorable prognosis and response to therapy compared to their wildtype counterparts.